Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17022083 | 0.88 | TAS1R3 (0.49) | TAS1R3TAS1R1TAS1R2DRD4LMNA | |
| SCHEMBL24619950 | 0.88 | TAS1R3 (0.49) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL24619886 | 0.88 | TAS1R3 (0.49) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL29771906 | 0.87 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL24619536 | 0.87 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL28677537 | 0.86 | TAS1R3 (0.55) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL22501388 | 0.86 | TAS1R3 (0.55) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL13974108 | 0.85 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL17018837 | 0.85 | TRPV1 (0.45) | TAS1R3TAS1R1TAS1R2DRD4LMNA | |
| SCHEMBL29771900 | 0.85 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220152-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | Hepagene Therapeutics (HK) Limited (HK) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220152-A1 | BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS | BIRC5, BIRC2, BIRC3 | TAS1R3 4578/4885TAS1R1 4403/4885TAS1R2 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.